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Inclusion body myopathy with
Paget disease and frontotemporal
dementia (IBMPFD): clinical
features including sphincter
disturbance in a large pedigree
Autosomal dominant inclusion body myo-
pathy (IBM) associated with Paget disease of
bone (PDB) and frontotemporal dementia
(FTD), or IBMPFD, is a rare recently
described multisystem disorder caused by
missense mutations of the valosin-contain-
ing protein (VCP) gene on chromosome
9p13–p12 (OMIM 605382).1 Recognised fea-
tures include proximal and distal weakness,
early-onset PDB, early-onset FTD and cardi-
omyopathy.1–3 Here we report the clinical
features of a large affected kindred.
PATIENTS AND METHODS
A large extended British family was identi-
fied with the condition (VS and AJ). Clinical
information was obtained by interviewing
patients, neurological examination of five
living patients and reviewing medical
records. Patients were investigated where
possible with MRI of brain, spine and pelvic
muscles, neurophysiology and anorectal
physiology, muscle biopsy, Addenbrookes
Cognitive Examination—Revised, skull,
lumbar spine and pelvic x rays, creatine
kinase and alkaline phosphatase. Mutation
analysis of VCP was performed on four
affected members and one unaffected refer-
ence member from this family. Genomic
DNA, extracted from peripheral blood via
standard methods, was analysed in duplicate
for each subject.
RESULTS
VCP mutation analysis of four affected
individuals (II:18, III:13, III:14, III:15; online
figure 1) showed a heterozygous c.464GRA
nucleotide substitution in exon 5 of the VCP
protein (p.R155H), a substitution not
detected in an unaffected maternal brother
(II:20) confirming mutation segregation
within the family. This mutation has been
previously identified.1
CLINICAL FEATURES
The pedigree of this five-generation IBMPFD
family with 18 affected members (12 men,
six women) is consistent with an autosomal
dominant pattern of inheritance (online
fig 1). Affected members presented with
proximal and axial weakness diagnosed as
motor neuron disease (MND) or other
muscular dystrophies (online table 1). Eight
members then proceeded to develop demen-
tia. PDB was not found in the retrospective
notes. The mean age of muscle weakness
onset was 34 (n = 9; range 20–49). The mean
duration of the illness to death, when
recorded, was 17 years (n = 8; range 10–
30). A detailed summary of the current
clinical features and investigations and those
from the retrospective notes for this large
pedigree are presented in online table 1. Four
members of the pedigree were found to have
dilated cardiomyopathy following echocar-
diography, two with mild shortness of
breath on exertion. All affected members
have been treated with angiotensin-convert-
ing enzyme inhibitors, one patient with
symptomatic improvement.
Five members of the extended pedigree
had symptoms of sphincter disturbance
presenting as urge incontinence (n = 5),
Figure 1 MRI from members of the reported pedigree. (A) T2-weighted coronal image of II:18.
There is moderate atrophy of the left temporal lobe cortex. (B) T2-weighted sagittal image of the
thoracolumbar spine in the same subject showing marked atrophy of the distal cord. (C) FLAIR axial
image of III:14 demonstrating scattered white matter high signal in the white matter. (D) Fat
suppressed T2 coronal imaging of the pelvis and upper thigh in III:14 demonstrating marked
asymmetrical wasting of the adductor and hamstring muscles on the left side (black arrowheads)
compared with the more normal right side (white arrowheads).
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faecal incontinence (n = 4) or erectile dys-
function (n = 3; all male patients). Anorectal
electrophysiology was performed in two
patients, both consistent with bilateral
pudendal neuropathies (Web table 1). MRI
studies (fig 1) showed: scattered cerebral
white matter hyperintensities in all three
patients in whom this test was performed;
asymmetrical left frontotemporal atrophy
consistent with clinical FTD and an atrophic
cord especially around the conus in II:18;
and fatty change and atrophy of the gluteal
muscles and low muscle volume in the
quadriceps and hamstring groups in III:14.
A muscle biopsy from II:14 is shown in
online fig 2.
DISCUSSION
IBMPFD presents as a multisystem disorder
affecting brain, skeletal and cardiac muscle,3
spinal cord and bone.1 4 The R155H muta-
tion, an arginine-to-histidine substitution in
the N-terminal CDC48 domain of the VCP
protein, results in loss of VCP function5 and
is found exclusively in individuals affected
with IBMPFD.1 Clinical reports of this
disease are scarce.1 2 4 Family members
usually presented with proximal weakness,
progressing to wheelchair disability and
premature death. The average age of muscle
weakness onset, as a familial average, was
34, contrasting with previous studies (432
and 574). The dementia frequency within
this pedigree was 44% compared with 30%,1
70%,4 and 100%4 in other studies. As some
patients may have prematurely died of
myopathy- or cardiomyopathy-related com-
plications, it was difficult to assess FTD
penetrance.
Four out of five investigated members of
this pedigree had echocardiographic features
of cardiomyopathy.3 This is the first clinical
description of cardiomyopathy in a molecu-
larly confirmed VCP mutation. Recent
postmortem findings have found a dilated
and hypertrophic cardiomyopathy in one
patient with IBMPFD.3
The new observation in this pedigree is
the presence of prominent sphincter distur-
bance involving bladder, bowel and erectile
function in all five assessed pedigree mem-
bers. Other factors could partially explain
these symptoms: for example, functional
obstructive defaecation may be partly
responsible for the clinical picture of puden-
dal neuropathy seen in III:13. However, this
is associated with a reduction in sphincter
tone, a feature not seen during anorectal
physiology. Moreover, III:15 had pudendal
neuropathy with no history of longstanding
constipation. In III:13, III:14 and III:15,
erectile failure may be partly explained by
psychogenic factors. Nonetheless, the simi-
larity of sphincter symptoms between all
patients and in particular four relatively
young patients (III:3, III:13, III:14, III:15) is
striking. We therefore conclude that
IBMPFD is likely to be associated with
sphincter disturbance. The presence of
spinal cord atrophy in one patient (II:18)
and previous work showing ubiquitin-posi-
tive nuclear inclusion bodies in the spinal
cord in IBMPFD4 suggest that sphincter
disturbance in IBMPFD could arise from
both spinal cord and nerve pathology.
Brain MRI demonstrated a mild excess of
white matter abnormalities in all three
examined. Right temporal lobe atrophy and
cord atrophy were seen in an older patient,
correlating with her clinical FTD. This is in
agreement with one other MRI brain study
of IBMPFD,3 while another described pro-
gressive cerebral atrophy with prominent
callosal and frontal white matter loss.5
Spinal cord atrophy is a previously unde-
scribed feature of IBMPFD and is consistent
with pathological findings of spinal cord
inclusion bodies.4 A recent report describes
MRI muscle findings in IBMPFD of ‘‘fatty
degeneration’’ throughout predominantly
proximal muscle groups,3 in agreement with
current findings.
Members of this pedigree had been pre-
viously given other diagnoses including
various muscular dystrophies and spinal
muscular atrophy. MND had been diag-
nosed in some patients because of denerva-
tion on neurophysiology (online table 1).
In conclusion, IBMPFD is a multisystem
disorder, which should be considered in the
differential diagnosis of autosomal domi-
nant neuromuscular disorders, especially
when there is a prominent history of
dementia or ‘‘MND.’’ Sphincter involve-
ment is a likely associated clinical feature
of the disease.
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CORRECTION
doi:10.1136/jnnp.2008.158303corr1
M P T Lunn, H J Willison. Diagnosis and
treatment of inflammatory neuropathies (J
Neurol Neurosurg Psychiatry 2009;80:249–58).
There is a dosage error in this paper. In the
last paragraph on page 255 the dose of
prednisolone should be 1mg/kg not 1g/kg as
printed.
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